Dabigatran (Pradaxa, Boehringer Ingelheim) may have a safety advantage over rivaroxaban (Xarelto, Bayer), say international experts after findings from the first ‘real world’ study comparing the two NOACS show that rivaroxaban was associated with a greater and more severe bleeding risk. But Australian experts are cautious about drawing such prescriptive conclusions from an observational study. ...
Caution needed over real-world NOAC study: experts
By Sunalie Silva
14 Oct 2016